Published in Trans Am Ophthalmol Soc on January 01, 2003
Topical voriconazole as a novel treatment for fungal keratitis. Antimicrob Agents Chemother (2006) 1.20
Treatment of two postoperative endophthalmitis cases due to Aspergillus flavus and Scopulariopsis spp. with local and systemic antifungal therapy. BMC Infect Dis (2007) 0.99
Small interfering RNA-mediated suppression of Ccl2 in Müller cells attenuates microglial recruitment and photoreceptor death following retinal degeneration. J Neuroinflammation (2012) 0.98
Pharmacokinetics and safety of intravitreal caspofungin. Antimicrob Agents Chemother (2014) 0.88
Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis. Clin Ophthalmol (2010) 0.84
Combination of intracameral and intrastromal voriconazole in the treatment of recalcitrant Acremonium fungal keratitis. Middle East Afr J Ophthalmol (2012) 0.84
Effects of anti-VEGF agents on rat retinal Müller glial cells. Mol Vis (2010) 0.80
Retinal function assessed by ERG before and after induction of ocular aspergillosis and treatment by the anti-fungal, micafungin, in rabbits. Doc Ophthalmol (2005) 0.80
Prospective open-label study of the administration of two-percent voriconazole eye drops. Antimicrob Agents Chemother (2009) 0.80
Intravitreal voriconazole as primary treatment for endogenous Aspergillus endophthalmitis. BMJ Case Rep (2009) 0.79
Effect of formulation factors on in vitro transcorneal permeation of voriconazole from aqueous drops. J Adv Pharm Technol Res (2013) 0.77
Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye. Invest Ophthalmol Vis Sci (2010) 0.77
FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy. PLoS One (2015) 0.76
Microglia-derived IL-1β promotes chemokine expression by Müller cells and RPE in focal retinal degeneration. Mol Neurodegener (2017) 0.75
Excellent outcome of Aspergillous endophthalmitis in a case of allergic bronchopulmonary aspergillosis. Indian J Ophthalmol (2014) 0.75
Topical and oral voriconazole in the treatment of fungal keratitis. Korean J Ophthalmol (2009) 0.75
Intravitreal voriconazole for the treatment of Aspergillus chorioretinitis. Int Ophthalmol (2011) 0.75
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev (1998) 9.76
Amphotericin B: 30 years of clinical experience. Rev Infect Dis (1990) 5.82
Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev (1999) 5.51
In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother (2002) 3.36
In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother (1998) 3.06
In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol (1999) 2.82
In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia (2001) 2.64
Recovery phase of the murine rod photoresponse reconstructed from electroretinographic recordings. J Neurosci (1996) 2.50
Antifungal activity of the new azole UK-109, 496 (voriconazole). Mycoses (1999) 1.60
Voriconazole -- better chances for patients with invasive mycoses. Eur J Med Res (2002) 1.59
GCAP1 rescues rod photoreceptor response in GCAP1/GCAP2 knockout mice. EMBO J (2002) 1.49
A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother (1997) 1.41
Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol (2000) 1.28
Impaired hyaloidal circulation function and uncoordinated ocular growth patterns in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci (1998) 1.12
Toxicity of intravitreal injection of amphotericin B. Am J Ophthalmol (1973) 1.12
Voriconazole: a new triazole antifungal. Ann Pharmacother (2000) 1.06
In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagn Microbiol Infect Dis (1999) 1.03
Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med Mycol (1998) 1.01
Activity of voriconazole against corneal isolates of Scedosporium apiospermum. Cornea (2003) 0.99
Ocular uptake of fluconazole following oral administration. Arch Ophthalmol (1990) 0.92
Retinal toxicity of amphotericin B in vitrectomised versus non-vitrectomised eyes. Br J Ophthalmol (1986) 0.82
Antifungal activity of a new triazole, voriconazole (UK-109496), against clinical isolates of Aspergillus spp. J Infect Chemother (2000) 0.81
Toxicity and efficacy of intravitreal injection of spartanamicin B in the treatment of Candida endophthalmitis. Int Ophthalmol (1998) 0.80
Vitrectomy and systemic fluconazole for treatment of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers (1996) 0.80
Retinal toxicity of intravitreally injected faeriefungin. Ophthalmic Surg (1994) 0.80
Retinal toxicity and in vitro efficacy study of cilofungin (LY121019). Ophthalmic Surg (1990) 0.80
The effect of experimental glaucoma on vitreous volume. Metab Pediatr Syst Ophthalmol (1982) 0.79
Update on antifungal agents. Pediatr Infect Dis J (2001) 0.79
Age-related macular degeneration. N Engl J Med (2008) 7.49
Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology (2011) 4.96
Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol (2003) 4.78
Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology (2002) 2.51
Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology (2012) 2.32
Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol (2004) 2.15
Light-evoked excitatory and inhibitory synaptic inputs to ON and OFF alpha ganglion cells in the mouse retina. J Neurosci (2003) 2.10
Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology (2006) 2.05
Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol (2005) 1.98
Spectral-domain optical coherence tomography: a comparison of modern high-resolution retinal imaging systems. Am J Ophthalmol (2010) 1.94
Vitreous and aqueous penetration of orally administered gatifloxacin in humans. Arch Ophthalmol (2003) 1.69
The transcription factor Bhlhb4 is required for rod bipolar cell maturation. Neuron (2004) 1.69
Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol (2005) 1.65
SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron (2003) 1.64
BETA2/NeuroD1 null mice: a new model for transcription factor-dependent photoreceptor degeneration. J Neurosci (2003) 1.61
Twenty-year follow-up for scleral buckling. Arch Ophthalmol (2002) 1.58
Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1. Antioxid Redox Signal (2008) 1.58
Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol (2008) 1.58
Symptomatic posterior vitreous detachment and the incidence of delayed retinal breaks: case series and meta-analysis. Am J Ophthalmol (2007) 1.55
Light-evoked current responses in rod bipolar cells, cone depolarizing bipolar cells and AII amacrine cells in dark-adapted mouse retina. J Physiol (2004) 1.53
Involution of threshold retinopathy of prematurity after diode laser photocoagulation. Ophthalmology (2004) 1.51
GCAP1 rescues rod photoreceptor response in GCAP1/GCAP2 knockout mice. EMBO J (2002) 1.49
Prospective comparison of cirrus and stratus optical coherence tomography for quantifying retinal thickness. Am J Ophthalmol (2008) 1.45
Clinical and molecular characterization of a family with autosomal recessive cornea plana. Arch Ophthalmol (2005) 1.44
Geographic atrophy: clinical impact and emerging treatments. Ophthalmic Surg Lasers Imaging Retina (2015) 1.43
Strategic planning ensures surgical success in cases of proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging Retina (2015) 1.39
Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging (2005) 1.38
Management of retinal breaks and conditions predisposing to retinal detachment. Compr Ophthalmol Update (2006) 1.38
Genetic dissection of rod and cone pathways in the dark-adapted mouse retina. J Neurophysiol (2009) 1.35
Impaired photoreceptor protein transport and synaptic transmission in a mouse model of Bardet-Biedl syndrome. Vision Res (2007) 1.33
Phenotypic characterization of Bbs4 null mice reveals age-dependent penetrance and variable expressivity. Hum Genet (2006) 1.32
Guanylate cyclase-activating protein (GCAP) 1 rescues cone recovery kinetics in GCAP1/GCAP2 knockout mice. Proc Natl Acad Sci U S A (2003) 1.31
Relative contributions of rod and cone bipolar cell inputs to AII amacrine cell light responses in the mouse retina. J Physiol (2007) 1.30
Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol (2008) 1.30
Low-conductance HCN1 ion channels augment the frequency response of rod and cone photoreceptors. J Neurosci (2009) 1.23
Gene therapy prevents photoreceptor death and preserves retinal function in a Bardet-Biedl syndrome mouse model. Proc Natl Acad Sci U S A (2011) 1.22
Anatomical success rate after primary three-port lens-sparing vitrectomy in stage 5 retinopathy of prematurity. Retina (2006) 1.20
Expression of VLDLR in the retina and evolution of subretinal neovascularization in the knockout mouse model's retinal angiomatous proliferation. Invest Ophthalmol Vis Sci (2008) 1.19
Update on retinal detachment surgery. Curr Opin Ophthalmol (2013) 1.19
Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Arch Ophthalmol (2006) 1.17
Stratum-by-stratum projection of light response attributes by retinal bipolar cells of Ambystoma. J Physiol (2004) 1.15
Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina (2014) 1.15
Development of cholinergic amacrine cells is visual activity-dependent in the postnatal mouse retina. J Comp Neurol (2005) 1.13
A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology (2009) 1.13
Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration. Retina (2010) 1.12
Effects of elevated intraocular pressure on mouse retinal ganglion cells. Vision Res (2005) 1.12
The retinoid cycle and retina disease. Vision Res (2003) 1.11
A mouse model of elevated intraocular pressure: retina and optic nerve findings. Trans Am Ophthalmol Soc (2003) 1.11
Elevated intraocular pressure causes inner retinal dysfunction before cell loss in a mouse model of experimental glaucoma. Invest Ophthalmol Vis Sci (2013) 1.10
Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol (2002) 1.09
How do tonic glutamatergic synapses evade receptor desensitization? J Physiol (2008) 1.09
Physiological characterization and functional heterogeneity of narrow-field mammalian amacrine cells. J Physiol (2011) 1.09
Macular hole in cat scratch disease. Am J Ophthalmol (2005) 1.09
Direct rod input to cone BCs and direct cone input to rod BCs challenge the traditional view of mammalian BC circuitry. Proc Natl Acad Sci U S A (2009) 1.08
Insights into inpatients with poor vision: A high value proposition. J Hosp Med (2015) 1.07
25-gauge vitrectomy using sulfur hexafluoride and no prone positioning for repair of macular holes. Retina (2008) 1.06
Receptive fields of retinal bipolar cells are mediated by heterogeneous synaptic circuitry. J Neurosci (2009) 1.05
Optical coherence tomography of idiopathic juxtafoveolar telangiectasia. Ophthalmic Surg Lasers Imaging (2006) 1.05
Mislocalization and degradation of human P23H-rhodopsin-GFP in a knockin mouse model of retinitis pigmentosa. Invest Ophthalmol Vis Sci (2011) 1.04
Endogenous endophthalmitis secondary to vancomycin-resistant enterococci infection. Retina (2003) 1.04
Connexin35/36 gap junction proteins are expressed in photoreceptors of the tiger salamander retina. J Comp Neurol (2004) 1.04
Photoprotection of human retinal pigment epithelium cells against blue light-induced apoptosis by melanin free radicals from Sepia officinalis. Proc Natl Acad Sci U S A (2006) 1.04
Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch Ophthalmol (2004) 1.03
Relative contributions of bipolar cell and amacrine cell inputs to light responses of ON, OFF and ON-OFF retinal ganglion cells. Vision Res (2002) 1.03
Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol (2006) 1.03
Physiological properties of rod photoreceptor electrical coupling in the tiger salamander retina. J Physiol (2005) 1.02
Long-term retinal toxicity of intravitreal commercially available preserved triamcinolone acetonide (Kenalog) in rabbit eyes. Invest Ophthalmol Vis Sci (2007) 1.02
Cystoid macular edema associated with fingolimod use for multiple sclerosis. JAMA Ophthalmol (2013) 1.02
Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clin Ophthalmol (2009) 1.02
The use of intraocular corticosteroids. Expert Opin Pharmacother (2009) 1.01
Segregation and integration of visual channels: layer-by-layer computation of ON-OFF signals by amacrine cell dendrites. J Neurosci (2002) 1.01
Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab. Eur J Ophthalmol (2011) 1.01
Anatomic success rate after 3-port lens-sparing vitrectomy in stage 4A or 4B retinopathy of prematurity. Ophthalmology (2005) 0.99
Intravitreal moxifloxacin: retinal safety study with electroretinography and histopathology in animal models. Invest Ophthalmol Vis Sci (2006) 0.99
Iris-sutured intraocular lenses for ectopia lentis in children. J Cataract Refract Surg (2008) 0.98
Ultra-widefield retinal imaging in the management of diabetic eye diseases. Ophthalmic Surg Lasers Imaging Retina (2014) 0.97
Characterization of ischemic index using ultra-widefield fluorescein angiography in patients with focal and diffuse recalcitrant diabetic macular edema. Am J Ophthalmol (2013) 0.97
Loss of VLDL receptor activates retinal vascular endothelial cells and promotes angiogenesis. Invest Ophthalmol Vis Sci (2008) 0.97
Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo. Vision Res (2010) 0.96
Electrical coupling, receptive fields, and relative rod/cone inputs of horizontal cells in the tiger salamander retina. J Comp Neurol (2006) 0.96
Retinal complications of bone marrow and solid organ transplantation. Curr Opin Ophthalmol (2003) 0.96